PharmaCyte Biotech Releases Assertion on Nasdaq Uplisting and Present-day Organization Concentration

LAGUNA HILLS, Calif., August 16, 2021–(Business enterprise WIRE)–PharmaCyte Biotech, Inc. (NASDAQ: PMCB) (PharmaCyte or Organization), a biotechnology firm targeted on developing mobile therapies for most cancers and diabetic issues using its signature are living-cell encapsulation technological know-how, Mobile-in-a-Box®, today introduced a statement from Kenneth L. Waggoner, the Chief Government Officer of PharmaCyte, concerning the Company’s latest listing on Nasdaq and the Company’s recent organization aim.

Mr. Waggoner said, “Becoming a Nasdaq-outlined company is an significant milestone in PharmaCyte’s lifecycle as we proceed to execute on our initiatives to develop extensive time period shareholder worth and to develop our therapies for pancreatic cancer, diabetes and other hard-to-deal with health conditions. We believe remaining a Nasdaq-stated organization will assistance elevate our public profile, increase our shareholder base, enhance liquidity and increase shareholder benefit.

“In Q4 2020, we assembled a team of regulatory and scientific industry experts to do the job by the U.S. Foodstuff and Drug Administration’s (Fda) scientific maintain requests to accomplish an open Investigational New Drug Application (IND). Our existing concentrate is to comply with the FDA’s requests as quickly as possible. When we make considerable development toward that aim, we will advise our shareholders and the investment neighborhood.

“As we were functioning on the FDA’s requests, we formulated a program to increase the two our money composition and our position in the current market by creating PharmaCyte more beautiful to the investment decision group and uplisting to a nationwide exchange. Our previous share composition and price tag made it impossible to keep on to fund our work, attain an open up IND and to fund a medical trial in domestically state-of-the-art, inoperable pancreatic most cancers (LAPC) as an OTC Marketplaces Team business.

“Soon after a vital reverse inventory break up, we had been ready to draw in various institutional investors who ended up intrigued in our one of a kind technological know-how and our exceptionally minimal float. It was this curiosity that permitted us to cull together a host of institutional investors to be a part of our community offering and raise $15 million. This funding is very important for us to accomplish our work towards an open up IND and to commence to fund our scientific demo in LAPC. Due to the fact of the Company’s restructuring, we have been capable to carry out a important money increase although sustaining an exceptionally low float.

“By listing on Nasdaq, we can leverage the Nasdaq shareholder engagement and intelligence applications, visibility system, issuer advocacy and assistance, and customer community that will give bigger possibilities for us to succeed in today’s aggressive marketplace. Also, we have significantly enhanced obtain to capital to fund our growth and expansion designs. Nasdaq also brings us enhanced transparency and innovation in its trading system for providers in the biotechnology, prescribed drugs and technological innovation sectors.

“We are excited to be listed as a community business with Nasdaq. Considering that its inception, Nasdaq has captivated preeminent firms in their respective business sectors. We are happy, certainly very pleased, to have joined so quite a few other prosperous organizations that trade on Nasdaq.”

About PharmaCyte Biotech

PharmaCyte Biotech, Inc. is a biotechnology company developing mobile therapies for most cancers and diabetes based mostly upon a proprietary cellulose-based mostly dwell cell encapsulation technological innovation acknowledged as “Cell-in-a-Box®.” This engineering is being employed as a system upon which therapies for several types of most cancers and diabetic issues are remaining made.

PharmaCyte’s solution prospect for most cancers requires encapsulating genetically engineered human cells that convert an inactive chemotherapy drug into its energetic or “cancer-killing” sort. For pancreatic most cancers, these encapsulated cells are implanted in the blood supply to the patient’s tumor as shut as attainable to the web-site of the tumor. The moment implanted, the chemotherapy prodrug ifosfamide that is usually activated in the liver is given intravenously at just one-3rd the typical dose. The ifosfamide is carried by the circulatory system to in which the encapsulated cells have been implanted. When the ifosfamide flows by means of pores in the capsules, the live cells inside act as a “bio-synthetic liver” and activate the chemotherapy prodrug ifosfamide at the site of the most cancers.

PharmaCyte’s product applicant for Form 1 diabetes and insulin-dependent Variety 2 diabetes includes encapsulating a human liver mobile line that has been genetically engineered to produce and launch insulin in reaction to the stages of blood sugar in the human overall body. PharmaCyte is also contemplating the use of genetically modified stem cells to handle diabetes. The encapsulation of the cell traces will be done using the Cell-in-a-Box® know-how. After the encapsulated cells are implanted in a diabetic client, we anticipate that they will perform as a “bio-synthetic pancreas” for purposes of insulin manufacturing.

Protected Harbor

This press release could comprise ahead-seeking statements in the this means of the Non-public Securities Litigation Reform Act of 1995 that express the latest beliefs and anticipations of the administration of PharmaCyte. Any statements contained in this press launch that do not describe historic details are ahead-wanting statements that are matter to hazards and uncertainties that could bring about real final results, efficiency, and achievements to differ materially from those people reviewed in this kind of forward-on the lookout statements. Aspects that could have an affect on our true outcomes incorporate our potential to sustain the listing of our prevalent inventory on a countrywide securities exchange, raise the vital money to fund our functions and to locate companions to supplement our capabilities and methods, satisfactorily address the issues lifted by the Food and drug administration to have the scientific keep removed on our IND so that we might carry on with our prepared scientific trial for LAPC, as nicely as such other aspects that are integrated in our periodic reports on Type 10-K and Variety 10-Q that we file with the SEC. These forward-seeking statements are built only as of the day hereof, and we undertake no obligation to update or revise the ahead-searching statements, other than as normally necessary by legislation, whether or not mainly because of new information, potential events or or else.

A lot more data about PharmaCyte Biotech can be observed at www.PharmaCyte.com. Information and facts may perhaps also be received by calling PharmaCyte’s Trader Relations Division.

Perspective supply model on businesswire.com: https://www.businesswire.com/information/house/20210816005165/en/

Contacts

Dr. Gerald W. Crabtree
Trader Relations:
PharmaCyte Biotech, Inc.
Trader Relations Section
Telephone: 917.595.2856
E-mail: [email protected]